tirzepatide weight loss trial results The SURMOUNT-MAINTAIN Phase 3b is testing if adults with obesity can maintain by continuing or reducing (vs placebo) after achieving on the highest dose. #Tirzepatide https://t.co/FHyoDXDEYv The Next Frontier of Weight

This temporary dizziness usually resolves within 37 days

The marketing also makes bold claims like "Lose 27 lbs in 60 Days" that feel overly promotional

Patients with severe renal impairment, recent abdominal surgery, or uncontrolled diabetic complications require careful provider assessment before starting

Oral GLP-1 medications may be a reasonable option for: Patients early in their weight loss journey Patients with mild to moderate weight loss goals Patients who strongly prefer to avoid injections They may be less ideal for: Patients who have had bariatric surgery Patients needing significant weight loss Patients who have not responded to oral medications in the past The decision is not just about preference